The human host response to monkeypox infection: a proteomic case series study
The rapid rise of monkeypox (MPX) cases outside previously endemic areas prompts for a better understanding of the disease. We studied the plasma proteome of a group of MPX patients with a similar infection history and clinical manifestation typical for the current outbreak. We report that MPX in th...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Springer
2022
|
| _version_ | 1826315023247474688 |
|---|---|
| author | Wang, Z Tober‐Lau, P Farztdinov, V Lemke, O Schwecke, T Steinbrecher, S Muenzner, J Kriedemann, H Sander, LE Hartl, J Mülleder, M Ralser, M Kurth, F |
| author_facet | Wang, Z Tober‐Lau, P Farztdinov, V Lemke, O Schwecke, T Steinbrecher, S Muenzner, J Kriedemann, H Sander, LE Hartl, J Mülleder, M Ralser, M Kurth, F |
| author_sort | Wang, Z |
| collection | OXFORD |
| description | The rapid rise of monkeypox (MPX) cases outside previously endemic areas prompts for a better understanding of the disease. We studied the plasma proteome of a group of MPX patients with a similar infection history and clinical manifestation typical for the current outbreak. We report that MPX in this case series is associated with a strong plasma proteomic response among nutritional and acute phase response proteins. Moreover, we report a correlation between plasma proteins and disease severity. Contrasting the MPX host response with that of COVID‐19, we find a range of similarities, but also important differences. For instance, CFHR1 is induced in COVID‐19, but suppressed in MPX, reflecting the different roles of the complement system in the two infectious diseases. Of note, the spatial overlap in response proteins suggested that a COVID‐19 biomarker panel assay could be repurposed for MPX. Applying a targeted protein panel assay provided encouraging results and distinguished MPX cases from healthy controls. Hence, our results provide a first proteomic characterization of the MPX human host response and encourage further research on protein‐panel assays in emerging infectious diseases. |
| first_indexed | 2024-12-09T03:18:28Z |
| format | Journal article |
| id | oxford-uuid:670f4032-598a-4306-a5ec-30e473f5132e |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-12-09T03:18:28Z |
| publishDate | 2022 |
| publisher | Springer |
| record_format | dspace |
| spelling | oxford-uuid:670f4032-598a-4306-a5ec-30e473f5132e2024-10-28T20:12:49ZThe human host response to monkeypox infection: a proteomic case series studyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:670f4032-598a-4306-a5ec-30e473f5132eEnglishJisc Publications RouterSpringer2022Wang, ZTober‐Lau, PFarztdinov, VLemke, OSchwecke, TSteinbrecher, SMuenzner, JKriedemann, HSander, LEHartl, JMülleder, MRalser, MKurth, FThe rapid rise of monkeypox (MPX) cases outside previously endemic areas prompts for a better understanding of the disease. We studied the plasma proteome of a group of MPX patients with a similar infection history and clinical manifestation typical for the current outbreak. We report that MPX in this case series is associated with a strong plasma proteomic response among nutritional and acute phase response proteins. Moreover, we report a correlation between plasma proteins and disease severity. Contrasting the MPX host response with that of COVID‐19, we find a range of similarities, but also important differences. For instance, CFHR1 is induced in COVID‐19, but suppressed in MPX, reflecting the different roles of the complement system in the two infectious diseases. Of note, the spatial overlap in response proteins suggested that a COVID‐19 biomarker panel assay could be repurposed for MPX. Applying a targeted protein panel assay provided encouraging results and distinguished MPX cases from healthy controls. Hence, our results provide a first proteomic characterization of the MPX human host response and encourage further research on protein‐panel assays in emerging infectious diseases. |
| spellingShingle | Wang, Z Tober‐Lau, P Farztdinov, V Lemke, O Schwecke, T Steinbrecher, S Muenzner, J Kriedemann, H Sander, LE Hartl, J Mülleder, M Ralser, M Kurth, F The human host response to monkeypox infection: a proteomic case series study |
| title | The human host response to monkeypox infection: a proteomic case series study |
| title_full | The human host response to monkeypox infection: a proteomic case series study |
| title_fullStr | The human host response to monkeypox infection: a proteomic case series study |
| title_full_unstemmed | The human host response to monkeypox infection: a proteomic case series study |
| title_short | The human host response to monkeypox infection: a proteomic case series study |
| title_sort | human host response to monkeypox infection a proteomic case series study |
| work_keys_str_mv | AT wangz thehumanhostresponsetomonkeypoxinfectionaproteomiccaseseriesstudy AT toberlaup thehumanhostresponsetomonkeypoxinfectionaproteomiccaseseriesstudy AT farztdinovv thehumanhostresponsetomonkeypoxinfectionaproteomiccaseseriesstudy AT lemkeo thehumanhostresponsetomonkeypoxinfectionaproteomiccaseseriesstudy AT schwecket thehumanhostresponsetomonkeypoxinfectionaproteomiccaseseriesstudy AT steinbrechers thehumanhostresponsetomonkeypoxinfectionaproteomiccaseseriesstudy AT muenznerj thehumanhostresponsetomonkeypoxinfectionaproteomiccaseseriesstudy AT kriedemannh thehumanhostresponsetomonkeypoxinfectionaproteomiccaseseriesstudy AT sanderle thehumanhostresponsetomonkeypoxinfectionaproteomiccaseseriesstudy AT hartlj thehumanhostresponsetomonkeypoxinfectionaproteomiccaseseriesstudy AT mullederm thehumanhostresponsetomonkeypoxinfectionaproteomiccaseseriesstudy AT ralserm thehumanhostresponsetomonkeypoxinfectionaproteomiccaseseriesstudy AT kurthf thehumanhostresponsetomonkeypoxinfectionaproteomiccaseseriesstudy AT wangz humanhostresponsetomonkeypoxinfectionaproteomiccaseseriesstudy AT toberlaup humanhostresponsetomonkeypoxinfectionaproteomiccaseseriesstudy AT farztdinovv humanhostresponsetomonkeypoxinfectionaproteomiccaseseriesstudy AT lemkeo humanhostresponsetomonkeypoxinfectionaproteomiccaseseriesstudy AT schwecket humanhostresponsetomonkeypoxinfectionaproteomiccaseseriesstudy AT steinbrechers humanhostresponsetomonkeypoxinfectionaproteomiccaseseriesstudy AT muenznerj humanhostresponsetomonkeypoxinfectionaproteomiccaseseriesstudy AT kriedemannh humanhostresponsetomonkeypoxinfectionaproteomiccaseseriesstudy AT sanderle humanhostresponsetomonkeypoxinfectionaproteomiccaseseriesstudy AT hartlj humanhostresponsetomonkeypoxinfectionaproteomiccaseseriesstudy AT mullederm humanhostresponsetomonkeypoxinfectionaproteomiccaseseriesstudy AT ralserm humanhostresponsetomonkeypoxinfectionaproteomiccaseseriesstudy AT kurthf humanhostresponsetomonkeypoxinfectionaproteomiccaseseriesstudy |